Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2024-04-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司独立董事2024年第一次专门会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of Jiangsu Sihuan Bio Co., Ltd. It includes approval of the 2023 profit distribution plan, 2024 related party transaction estimates, and the 2023 internal control evaluation report. The document is short (1230 characters) and primarily records meeting decisions and approvals by independent directors. It does not contain full financial statements or detailed financial data, nor is it a full annual or interim report. It is not a call transcript, earnings release, or capital update. It is a formal board/management related announcement about internal governance and approvals. Therefore, it fits best under Board/Management Information (MANG).
2024-04-29 Chinese
江苏四环生物股份有限公司公司董事会议事规则（2024年4月）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors' of 江苏四环生物股份有限公司. It details the composition, responsibilities, meeting procedures, voting rules, and other governance aspects of the company's board of directors. There is no financial data, earnings information, or audit content. It is a governance document outlining internal rules and board structure. Therefore, it fits the category of Governance Information (CGR). The document length is over 10,000 characters, indicating it is a full document, not just an announcement or summary.
2024-04-29 Chinese
江苏四环生物股份有限公司关于2023年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the company's 2023 annual profit distribution plan, specifically stating that no profit distribution will be made due to negative net profits and accumulated losses. It references the audit by Zhongshen Asia Pacific CPA and compliance with relevant Chinese securities regulations. The document is short (1156 characters) and serves as a notice about the profit distribution proposal to be submitted to the 2023 annual shareholders meeting. It does not contain detailed financial statements or comprehensive financial performance data, but rather a specific announcement about dividend policy and profit distribution plans. This fits the category of Notice of Dividend Amount (DIV) or related profit distribution announcements. Since it explicitly states the decision not to distribute profits and explains the reasons, it aligns best with the Notice of Dividend Amount (DIV) category, which includes announcements about dividend amounts or decisions regarding dividends. Confidence is high due to clear content and context.
2024-04-29 Chinese
江苏四环生物股份有限公司关于未弥补亏损达实收股本总额三分之一的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the company's accumulated losses reaching one-third of its paid-in capital, which requires submission to the shareholders' meeting for approval. It includes details about the financial condition as of December 31, 2023, reasons for the losses, and proposed measures to improve performance. The document is an official announcement of a corporate financial condition issue and related board resolutions, but it does not contain full financial statements or detailed financial performance data typical of an Annual Report or Interim Report. It is also not a report publication announcement or certification. The content aligns with a Regulatory Filing (RNS) as it is a regulatory disclosure about a significant financial condition event requiring shareholder approval, but not a full financial report or other specific filing type.
2024-04-29 Chinese
江苏四环生物股份有限公司公司章程（2024年4月）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for 江苏四环生物股份有限公司 (Jiangsu Sihuan Bioengineering Co., Ltd.). It includes comprehensive sections on company general provisions, business scope, share issuance, shareholder rights, shareholder meetings, board of directors, management, supervisory board, financial accounting, profit distribution, auditing, notifications, announcements, mergers, capital changes, and amendments to the charter. The content is legal and governance-related, focusing on the internal rules, shareholder meeting procedures, voting rights, board structure, and company governance practices. There is no indication of financial statements, audit reports, earnings data, or announcements of voting results. The document is not a report publication announcement but the actual governance document (company charter). Therefore, the most appropriate classification is Governance Information (CGR).
2024-04-29 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2023" from Jiangsu Sihuan Bio Co., Ltd. It details the independent director's background, independence statement, attendance at board and committee meetings, supervisory activities, and efforts to protect shareholder rights during the 2023 fiscal year. The content is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or audit opinions, nor is it a regulatory announcement or certification. This type of document fits best under Board/Management Information (MANG), as it relates to the activities and responsibilities of a board member rather than financial results or governance rules. The document length is 2665 characters, which is consistent with a detailed report but not a full annual report or audit report. Therefore, the classification is MANG with high confidence.
2024-04-29 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.